糖样胰高血糖素1受体激动剂与甲状腺癌：是否是值得关注的时候了？
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
发表日期：2023 Sep 01
作者：
Giuseppe Lisco, Anna De Tullio, Olga Disoteo, Giuseppina Piazzolla, Edoardo Guastamacchia, Carlo Sabbà, Vincenzo De Geronimo, Enrico Papini, Vincenzo Triggiani
来源：
DIABETES & METABOLISM
摘要：
肝素样胰高血糖素-1受体激动剂（GLP-1RAs）在2型糖尿病的管理方面发生了重大变化。然而，最近的回顾性队列研究数据表明，长期接触GLP-1RAs可能会增加2型糖尿病患者患乳头状和髓样甲状腺癌的风险。在此观点中，对胰高血糖素系统在甲状腺癌发生中的作用进行了回顾和批评性评论，旨在了解是否应该对该风险感到关注。尽管有证据支持，但猜测性假设应该得到验证，迫切需要进一步研究来阐明这个问题。
The Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes. However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue.